The m6A RNA methylation regulators related transcriptome for identification of pancreatic cancer subtypes and prognostic markers
Authors: 
Zhengshu Lu, Yanrui DingAuthors Info & Claims
Zhengshu Lu, Yanrui DingAuthors Info & ClaimsArticle No.: 38, Pages 1 - 5
Abstract
N6-methyladenosine (m6A) methylation is a major epigenetic modification of RNA that affects processes such as translation of related mRNAs and non-coding RNAs. A large number of recent studies have shown that m6A modifications play a crucial role in cancer development, however, the prognostic value of the m6A associated transcriptome in pancreatic cancer has rarely been investigated. The purpose of this study is to investigate the prognostic markers and prognostic subtypes of m6A RNA methylation regulators related transcriptome in pancreatic ductal adenocarcinoma (PDAC). First, we identified the m6A RNA methylation regulators related prognostic transcriptome by Pearson correlation analysis and univariate cox regression. Subsequently, to explore key prognostic markers from the prognostic transcriptome, we proposed a G-P model based on greedy algorithms and pruning algorithms to obtain a set of key genes CASC11, KRT14, PDZD4, and identified two high/low-risk subtypes of PDAC with significant prognostic differences based on key genes. The clustering Silhouette coefficients was 0.99 for the key genes. In addition, CASC11 and KRT14 were strongly upregulated in the high-risk subtype and PDZD4 was upregulated in the low-risk subtype, and their differential expression was significantly associated with survival. In conclusion, we revealed the typing role and prognostic value of the m6A RNA methylation regulators-associated transcriptome in PDAC and provided new insights for identifying predictive biomarkers and therapeutic targets for PDAC.
References
[1]
Frappart. Pierre-Olivier,Thomas G Hofmann.Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.” Cancers vol. 2020;10:2750.
[2]
Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30.
[3]
Bilimoria K.Y., Bentrem D.J., Ko C.Y., Stewart A.K., Winchester D.P., Talamonti M.S. National failure to operate on early stage pancreatic cancer. Ann. Surg. 2007;246:173–180.
[4]
Buanes T.A. Role of surgery in pancreatic cancer. World J. Gastroenterol. 2017;23:3765–3770.
[5]
Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013;369:1691–1703.
[6]
Goldstein D., El-Maraghi R.H., Hammel P. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. J. Natl. Cancer Inst. 2015;107
[7]
D Finkel; Y Groner. Methylations of adenosine residues (m6A) in pre-mRNA are important for formation of late simian virus 40 mRNAs. Virology, 131 (1983), pp. 409-425
[8]
Liu Zhicheng, Li Shanshan, Huang Shan, Wang Tao, Liu Zhicheng. N6-Methyladenosine Regulators and Related LncRNAs Are Potential to be Prognostic Markers for Uveal Melanoma and Indicators of Tumor Microenvironment Remodeling. Frontiers in Oncology. 2021;11: 2998.
[9]
Sun T, Wu R, Ming L. The Role of m6A RNA Methylation in Cancer. BioMed Pharmacother (2019) 112:108613.
[10]
Ping X, Sun B, Wang L, Xiao W, Yang X, Wang W, Mammalian WTAP is a Regulatory Subunit of the RNA N6-Methyladenosine Methyltransferase. Cell Res (2014) 24(2):177–89.
[11]
Yang Y, Hsu PJ, Chen Y, Yang Y. Dynamic Transcriptomic m6A Decoration: Writers, Erasers, Readers and Functions in RNA Metabolism. Cell Res (2018) 28(6):616–24.
[12]
Meyer KD, Jaffrey SR. Rethinking m6A Readers, Writers, and Erasers. Annu Rev Cell Dev Biol (2017) 33:319–42.
[13]
Ian A. Roundtree, Molly E. Evans, Tao Pan, Chuan He. Dynamic RNA Modifications in Gene Expression Regulation, Cell, 2017; 169:1187-1200
[14]
Yiling Ge, Tong Liu, Chuntao Wang, Yanqiu Zhang, Siyi Xu, Yiyi Ren, Yanlu Feng, Lihong Yin, Yuepu Pu & Geyu Liang. N6-methyladenosine RNA modification and its interaction with regulatory non-coding RNAs in colorectal cancer, RNA Biology,2021; 1974749:1-11
[15]
He L, Li H, Wu A, Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019 Dec 4;18(1):176.
[16]
Shao, Yanlin, Wong, Chui Eng, Shen, Lisha, Yu, Hao. N6-methyladenosine modification underlies messenger RNA metabolism and plant development. View Web of Science ResearcherID and ORCID. 2021; 63:102047
[17]
Rong-Zhang He, Jing Jiang, Di-Xian Luo, The functions of N6-methyladenosine modification in lncRNAs, Genes & Diseases, 2020, 7: 598-605,
[18]
Comprehensive analysis of mrna methylation reveals enrichment in 3' utrs and near stop codons. Cell, 149 (2012), pp. 1635-1646
[19]
Lan Q, Liu PY, Haase J, Bell JL, Huttelmaier S, Liu T. The critical role of RNA m(6) a methylation in Cancer. Cancer Res. 2019;79(7):1285–92.
[20]
Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019;112:108613.
[21]
Roundtree, I. A., Evans, M. E., Pan, T., & He, C*. "Dynamic RNA Modifications in Gene Expression Regulation." Cell 169.7 (2017):1187.
[22]
Shen Shen, Jingya Yan, Yize Zhang, Zihui Dong, Jiyuan Xing, Yuting He. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Annals of Translational Medicine.9.1(2021):59
[23]
Strobel, O., Neoptolemos, J., Jäger, D. & Büchler, M. W. Optimizing the outcomes of pancreatic cancer surgery. Nat. Rev. Clin. Oncol. 2019;16, 11–26.
[24]
Huang H, Weng H, Chen J. m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell (2020) 37:270–88.
[25]
Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer (2020) 19:88–105.
[26]
Chen XY, Zhang J, Zhu JS. The role of m6A RNA methylation in human cancer. Mol Cancer (2019) 18:103–11.
[27]
K. Taketo, M. Konno, A. Asai, J. Koseki, M. Toratani, T. Satoh, Y. Doki, M. Mori, H. Ishii, K. Ogawa. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int. J. Oncol., 52 (2018), pp. 621-629
[28]
Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, The Interplay Between M6a RNA Methylation and Noncoding RNA in Cancer. J Hematol Oncol (2019) 12:121.
[29]
Zhong Xiaoxiao, Li Jun, Wu Xin,et al. Identification of N6-Methyladenosine-Related LncRNAs for Predicting Overall Survival and Clustering of a Potentially Novel Molecular Subtype of Breast Cancer. Frontiers in Oncology. (2021)11:4195.
[30]
Huang Wei, Li Gen, Wang Zihang, Zhou Lin, A Ten-N6-Methyladenosine (m6A)-Modified Gene Signature Based on a Risk Score System Predicts Patient Prognosis in Rectum Adenocarcinoma. Frontiers in Oncology. (2021)10:3313
[31]
Moffitt, Richard A.; Marayati, Raoud; Flate, Elizabeth L. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. NATURE GENETICS,10, 47(2015): 1168-1178
[32]
Markus Gla, Agnes Dorn, Stefan Hüttelmaier and Monika Haemmerle and Tony Gutschner. Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. Cancers, 2020, 12(8):2077.
[33]
Cui, Y,Shen, GH,Zhou, D Wu, FL. CASC11 Overexpression Predicts Poor Prognosis and Regulates Cell Proliferation and Apoptosis in Ovarian Carcinoma. CANCER MANAGEMENT AND RESEARCH. 12(2020): 523-529.
[34]
Luo, HR, Xu, CD, Le, W, Ge, BJ, Wang, TR. lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. JOURNAL OF CELLULAR BIOCHEMISTRY. 8,120(2019): 13487-13493
[35]
Song H, Liu Y, Li XQ,Chen SH, Xie RZ, Chen DB,Gao HW,Wang GQ,Cai B,Yang XY. Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3-mediated E2F1 activation. CLINICAL AND TRANSLATIONAL MEDICINE. 10, 7(2020)
[36]
Wang XY,Han LN, Shan SM, Sun YX,Mao YM. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 10, 1(2017): 795-803
[37]
Isabella Kit-Nam Chin, Goretti Hoi-Yan Cheung, Hazel Yuk-Yan Kwok, Victor Wan-San Ma, Eunice Yuen-Ting Lau and William Chi-Shing Cho. The novel function of keratin 14 (KRT14) in regulating cancer stem cell properties in lung adenocarcinoma. AACR Annual Meeting,2018; Chicago, IL
[38]
Liu Weidong, Xu Zhentao, Zhou Jie, High Levels of HIST1H2BK in Low-Grade Glioma Predicts Poor Prognosis: A Study Using CGGA and TCGA Data. Frontiers in Oncology (2020)10:627
Recommendations
Predicting prognostic markers for glioma using gene co-expression network analysis
BCB '10: Proceedings of the First ACM International Conference on Bioinformatics and Computational BiologyIn this paper, we described our approach for selecting potential biomarkers based on gene co-expression network (GCN) analysis. We present an efficient GCN finding algorithm and applied it to search for predictive markers in glioblastoma using the TCGA ...
Whole transcriptome analysis reveals non-coding RNA's competing endogenous gene pairs as novel form of motifs in serous ovarian cancer
AbstractThe non-coding RNA (ncRNA) regulation appears to be associated to the diagnosis and targeted therapy of complex diseases. Motifs of non-coding RNAs and genes in the competing endogenous RNA (ceRNA) network would probably contribute to ...
Highlights- Gene expressions in some mRNA–ncRNA–mRNA motifs from the ceRNA network stably reverse between SOC and normal.
Integration of mRNA and protein expression data for the identification of potential biomarkers associated with pancreatic ductal adenocarcinoma
AbstractPancreatic ductal adenocarcinoma (PDAC) is one of the most death-dealing tumors, with a tremendously poor prognosis. Here, we, through interrogation of mRNA and protein data combined with a system biology approach, identified several key genes, ...
Comments
Information & Contributors
Information
Published In
December 2021
699 pages
ISBN:9781450385053
DOI:10.1145/3508546
Copyright © 2021 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 25 February 2022
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ACAI'21
ACAI'21: 2021 4th International Conference on Algorithms, Computing and Artificial Intelligence
December 22 - 24, 2021
Sanya, China
Acceptance Rates
Overall Acceptance Rate 173 of 395 submissions, 44%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 28Total Downloads
- Downloads (Last 12 months)5
- Downloads (Last 6 weeks)1
Reflects downloads up to 26 Jul 2024
Other Metrics
Citations
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format